History
2018 - 2022
Into the global healthcare market
- 2022
- Signed a MOU to co-develop new vaccine platforms (Hilleman Laboratories)
- Signed agreement to develop mRNA Vaccines (CEPI)
- Achieved adolescent authorization of 'Nuvaxovid' by KMFDS (Novavax, KMFDS)
- Submitted CMA to the EMA (SKYCovion)
- Submitted CMA to the MHRA (SKYCovion)
- Agreement to Manufacture COVID-19 Vaccine Containing Omicron Variant (Novavax)
- Achieved BLA of SKYCovione (KMFDS)
- Heid SK bioscience Global Forum
- Published first ESG report
- Achieved BLA of SKYTyphoid for export
- Achieved Turkish GMP Certification (TITCK)
- Agreed SKYvaricella distribution(PAHO)
- Signed Advance Purchase Agreement of GBP510(KDCA)
- Obtained additional EU-GMP Certification for COVID-19 Vaccine Facilities
- Authorized ‘Nuvaxovid’ by KMFDS (Novavax, KMFDS)
- 2021
- Earned the highest sales and operating profit
- Funded to develop a vaccine candidate against sarbecovirus (CEPI)
- Established ‘Park Mahnhoon Award’ (IVI)
- Submitted BLA submission for approval of the COVID-19 vaccine candidate, ‘NVX-CoV2373’ (Novavax, KMFDS)
- Signed an agreement to extend capacity reservations for manufacturing COVID-19 vaccines (CEPI)
- Started phase 3 trial for COVID-19 vaccine candidate 'GBP510'
- MOU for expansion of factories and site (North Gyeongsang Province, Andong city)
- Secured funding for phase 3 clinical trial of COVID-19 vaccine candidate 'GBP510' (CEPI)
- Obtained EU-GMP Certification for COVID-19 Vaccine Facilities
- New listed on KOSPI(Korea Composite Stock Price Index)
- Funded to develop a vaccine candidate against COVID-19 (SARS-CoV-2) variants (CEPI)
- Signed licensing & purchase agreement for Novavax’s COVID-19 vaccine candidate (Novavax, KDCA)
- GSK ‘GBP510’, a COVID-19 vaccine candidate, begins clinical trials for immunosuppressants
- Applied for permission to export typhoid vaccines
(IVI, Bill & Melinda Gates Foundation)
- 2020
- Started clinical trial for in-house produced COVID-19 vaccine (GBP510, NBP2001)
- Announced as WAVE2 by CEPI with GBP510 (COVID-19 vaccine)
- Exported SKY Varicella Inj. to Turkey
- Signed CDMO agreement with Novavax for COVID-19 vaccine
- Signed CMO agreement with AstraZeneca for the consigned production of COVID-19 vaccine
- Signed capacity reservation with CEPI for COVID-19 vaccine
- Secured funding for development of COVID-19 from Bill & Melinda Gates foundation
- Selected for national projects for COVID-19 vaccine
- Began independent development of COVID-19 vaccine
- Started phase 2 clinical trial for the next-generation pneumococcal conjugate vaccine co-developed with Sanofi Pasteur
- 2019
- Gained WHO PQ for SKY Cellflu prefilled syringe/SKY Cellflu Quadrivalent prefilled syringe (world’s first for cell-cultured influenza vaccine)
- Gained WHO PQ for SKY Varicella Inj. as world’s second
- Exports influenza vaccine, ‘SKYCellflu’, to Asian countries
- 2018
- MOU with Gyeonggi-bukdo and Andong-si for expansion of L HOUSE (Andong vaccine plant)
- SK bioscience launched (Spun off from the vaccine business sector of SK chemical)
- Signed agreement with Sanofi Pasteur to license out cell-culture technology for producing cell culture-derived influenza vaccines
- Launched SKY Varicella Inj.
2015 - 2017
The pinnacle of in-house technology
- 2017
- Launched Sky Zoster Inj., world’s second shingles vaccine
- Urgent supply of ‘SKYCellflu Quadrivalent’ Influenza Vaccine to Flu-ridden Myanmar
- Signed an agreement with international organization PATH to develop and produce pediatric enteritis vaccine for developing countries
- 2016
- Selected health and safety management indicators (L House [Andong Vaccine Plant]); received OHSAS18001, KOSHA18001 certification
- Launched SKYCellflu Quadrivalent, world’s first quadrivalent cell culture-derived influenza vaccine
- Gained approval for SKYPNEUMO, the first domestically produced PCV13 vaccine
- 2015
- Launched SKYCellflu, Korea’s first trivalent cell culture-derived influenza vaccine
2012 - 2014
Growth takes a leap forward
- 2014
- Established strategic partnership with Sanofi Pasteur for co-development of next-generation pneumococcal conjugate vaccine
- Received KGMP certification for L HOUSE (Andong Vaccine Plant)
- 2013
- Received LEED GOLD certification for L HOUSE (Andong Vaccine Plant)
- Established partnership with IVI (International Vaccine Institute) to collaborate on the development of a new typhoid conjugate vaccine
- 2012
- Completion of L HOUSE (Andong Vaccine Plant)
2001 - 2009
Into the domestic healthcare market
- 2005
- Established vaccine R&D center
- 2001
- Acquired Dongshin Pharm (vaccines, blood products)
